Logo image of VIVS

VIVOSIM LABS INC (VIVS) Stock Fundamental Analysis

NASDAQ:VIVS - Nasdaq - US68620A3023 - Common Stock - Currency: USD

1.99  +0.05 (+2.58%)

Fundamental Rating

2

VIVS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. VIVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VIVS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VIVS has reported negative net income.
In the past year VIVS has reported a negative cash flow from operations.
In the past 5 years VIVS always reported negative net income.
In the past 5 years VIVS always reported negative operating cash flow.
VIVS Yearly Net Income VS EBIT VS OCF VS FCFVIVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

VIVS's Return On Assets of -322.19% is on the low side compared to the rest of the industry. VIVS is outperformed by 95.19% of its industry peers.
Looking at the Return On Equity, with a value of -3402.47%, VIVS is doing worse than 85.38% of the companies in the same industry.
Industry RankSector Rank
ROA -322.19%
ROE -3402.47%
ROIC N/A
ROA(3y)-116.81%
ROA(5y)-91.68%
ROE(3y)-185.97%
ROE(5y)-134.22%
ROIC(3y)N/A
ROIC(5y)N/A
VIVS Yearly ROA, ROE, ROICVIVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

VIVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIVS Yearly Profit, Operating, Gross MarginsVIVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VIVS has more shares outstanding
VIVS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIVS Yearly Shares OutstandingVIVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VIVS Yearly Total Debt VS Total AssetsVIVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -137.55, we must say that VIVS is in the distress zone and has some risk of bankruptcy.
VIVS's Altman-Z score of -137.55 is on the low side compared to the rest of the industry. VIVS is outperformed by 98.04% of its industry peers.
VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -137.55
ROIC/WACCN/A
WACC10.1%
VIVS Yearly LT Debt VS Equity VS FCFVIVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.72 indicates that VIVS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.72, VIVS is doing worse than 91.80% of the companies in the same industry.
VIVS has a Quick Ratio of 0.72. This is a bad value and indicates that VIVS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of VIVS (0.72) is worse than 91.44% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.72
VIVS Yearly Current Assets VS Current LiabilitesVIVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.26% over the past year.
Looking at the last year, VIVS shows a very negative growth in Revenue. The Revenue has decreased by -50.20% in the last year.
Measured over the past years, VIVS shows a very negative growth in Revenue. The Revenue has been decreasing by -48.77% on average per year.
EPS 1Y (TTM)60.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-473%
Revenue 1Y (TTM)-50.2%
Revenue growth 3YN/A
Revenue growth 5Y-48.77%
Sales Q2Q%380%

3.2 Future

VIVS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.11% yearly.
VIVS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.71% yearly.
EPS Next Y96.31%
EPS Next 2Y40.15%
EPS Next 3Y25.11%
EPS Next 5YN/A
Revenue Next Year126.67%
Revenue Next 2Y63.71%
Revenue Next 3Y45.71%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIVS Yearly Revenue VS EstimatesVIVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M
VIVS Yearly EPS VS EstimatesVIVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2024 2025 2026 2027 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VIVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VIVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIVS Price Earnings VS Forward Price EarningsVIVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVS Per share dataVIVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as VIVS's earnings are expected to grow with 25.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.15%
EPS Next 3Y25.11%

More info and screens

0

5. Dividend

5.1 Amount

VIVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOSIM LABS INC

NASDAQ:VIVS (5/22/2025, 11:38:39 AM)

1.99

+0.05 (+2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)N/A N/A
Inst Owners16.11%
Inst Owner ChangeN/A
Ins Owners1.23%
Ins Owner ChangeN/A
Market Cap3.38M
Analysts45.71
Price TargetN/A
Short Float %8.73%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.02%
Min EPS beat(2)10.83%
Max EPS beat(2)47.21%
EPS beat(4)4
Avg EPS beat(4)30.5%
Min EPS beat(4)10.83%
Max EPS beat(4)47.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-37.39%
Min Revenue beat(2)-46.52%
Max Revenue beat(2)-28.26%
Revenue beat(4)1
Avg Revenue beat(4)-27.36%
Min Revenue beat(4)-62.09%
Max Revenue beat(4)27.45%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.73
P/FCF N/A
P/OCF N/A
P/B 9.29
P/tB 9.29
EV/EBITDA N/A
EPS(TTM)-4.49
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-5.95
FCFYN/A
OCF(TTM)-5.94
OCFYN/A
SpS0.07
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -322.19%
ROE -3402.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.81%
ROA(5y)-91.68%
ROE(3y)-185.97%
ROE(5y)-134.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.71%
Cap/Sales 10.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.72
Altman-Z -137.55
F-Score3
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)148.6%
Cap/Depr(5y)294.16%
Cap/Sales(3y)57.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-473%
EPS Next Y96.31%
EPS Next 2Y40.15%
EPS Next 3Y25.11%
EPS Next 5YN/A
Revenue 1Y (TTM)-50.2%
Revenue growth 3YN/A
Revenue growth 5Y-48.77%
Sales Q2Q%380%
Revenue Next Year126.67%
Revenue Next 2Y63.71%
Revenue Next 3Y45.71%
Revenue Next 5YN/A
EBIT growth 1Y36.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.51%
OCF growth 3YN/A
OCF growth 5YN/A